Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00567723 · ClinicalTrials.gov registry record
Long Term Treatment of End Stage Renal Disease Patients With Lanthanum Carbonate (Fosrenol)
A clinical trial, sponsored by Shire.
- Completed
- Registry status
- 2,105
- Enrollment target
NCT00567723 is a clinical trial that has completed, run by Shire. The registered enrollment target is 2,105 participants.
The verdict
NCT00567723 has completed, sponsored by Shire.
- COMPLETED
- Registry status
- 2,105 participants
- Enrollment target
Study Summary
Patients who have been treated with Fosrenol for a minimum of 12 consecutive weeks and are receiving dialysis will be followed for 5 years to compare mortality, bone fractures and incidence of selected morbidities to patients with no lanthanum exposure and to patients being treated for hyperphosphatemia with any marketed product.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,105 participants |
| Start Date | 2006-04-25 |
| Est. Completion | 2016-06-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00567723
The ClinicalTrials.gov registry entry for NCT00567723 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 2,105 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00567723 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00567723 about?
NCT00567723 is a clinical study titled "Long Term Treatment of End Stage Renal Disease Patients With Lanthanum Carbonate (Fosrenol)". Patients who have been treated with Fosrenol for a minimum of 12 consecutive weeks and are receiving dialysis will be followed for 5 years to compare mortality, bone fractures and incidence of selected morbidities to patients with no lanthanum exposure and to patients being treated for hyperphosphat...
What is the current status of trial NCT00567723?
This trial is currently completed. The enrollment target is 2,105 participants. The study started on 2006-04-25. Estimated completion is 2016-06-07.
Who is sponsoring clinical trial NCT00567723?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.